Common use of Further Obligations Clause in Contracts

Further Obligations. (a) Except as otherwise provided in Article 7, each party's responsibilities for patent prosecution activities pursuant to this Article 6 shall also include ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, (which term as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary License, each party hereto shall use the patent attorneys selected by UAB. In addition to the other obligations set forth in this Article 6, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with the correspondents with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 6, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 2 contracts

Sources: License Agreement (Idenix Pharmaceuticals Inc), License Agreement (Idenix Pharmaceuticals Inc)

Further Obligations. (a) Except as otherwise provided in Article 7Articles 9 and 18, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 8 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's ’s position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph Subsection8.5 (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 68, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 8 and 9, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Bukwang Patents, Triangle Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 68, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts [BUKWANG REDACTED] to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 78, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 7 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's ’s or its sublicensee's ’s position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicenseessublicensee, as applicable, may initiate, pursue or assume such patent prosecution activities, at as its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 67, each party undertakes to keep the other party and, if applicable applicable, such other party's ’s sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableapplicable and as appropriate for the licensed territory for a given sublicensee, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European applicable patent office counterparts with respect to the United States, Japan and European applicable patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees sublicensee in connection with any of its activities or the exercise of any of its rights pursuant to Article 67, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited tolimited, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity activities for which it has patent prosecution responsibility pursuant to this Article 67, it shall give the other party or its sublicense sublicensee notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio BUKWANG and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR agree that, during the term of any sublicensee agreementthe Pharmasset Sublicense Agreement, the rights of Novirio BUKWANG under this Article 6 7 shall be exercised, if at all, by its sublicense PHARMASSET with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement the Pharmasset Sublicense Agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR shall communicate with such sublicensee PHARMASSET directly. 25. Section 8.1(c) of the License Agreement shall be amended in its entirety as follows: If LICENSOR shall fail within ninety (90) days after receiving notice from BUKWANG of a potential infringement, to either (i) terminate such infringement or (ii) to institute, either jointly as provided in subparagraph (a) above or solely as provided in subparagraph (b) above and, thereafter, to prosecute such suit diligently, or (iii) if LICENSOR notifies BUKWANG that it does not plan to institute or join in such suit, BUKWANG may institute suit, and if required by law or required in order to bring suit or other legal action, name LICENSOR as a plaintiff. BUKWANG shall bear the entire cost of such litigation, including defending any counterclaims brought against LICENSOR and paying any judgments rendered against LICENSOR, and shall be entitled to retain the entire amount of any recovery or settlement. 26. A new Section 8.1(d) shall be added to the License Agreement as follows: In the event BUKWANG commences a suit pursuant to subparagraph (c), BUKWANG may deposit up to thirty percent (30%) of any royalties and milestone payments which are otherwise payable to LICENSOR during the pendency of such suit in an interest-bearing escrow account. Upon final resolution of such suit, BUKWANG shall provide LICENSOR with an accounting of the amounts escrowed and BUKWANG’s expenses incurred in such infringement suit. BUKWANG shall be entitled to offset any expenses which BUKWANG fails to recoup in such suit against the escrowed amounts. Any escrowed amounts (and interest thereon) in excess of BUKWANG’s unrecouped expenses shall be promptly paid to LICENSOR. 27. A new Section 8.3 shall be added to the License Agreement as follows:

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 712, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 11 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's ’s position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (aSubsection 11.5(a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 611, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervals, intervals with the correspondents all correspondence with the United States, Japan Japan, China and European patent office counterparts with respect to the United States, Japan Japan, China and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 8 and 9, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents patent in the Licensed Bukwang Patents, Eisai Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 611, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts [BUKWANG REDACTED] to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 7, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 shall also include ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's ’s or its sublicensee's ’s position with respect to any such patent prosecution activities, (which term as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall use the patent attorneys selected by UABPharmasset. In addition to the other obligations set forth in this Article 6, each party undertakes to keep the other party and, if applicable such other party's ’s sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with the correspondents with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 6, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 79 and 18, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 8 shall also include ex parte and inter partes all activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's ’s position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (aSection 8.5(a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 68, each party undertakes to keep the other party andparty, if applicable such other party's sublicensee throughout the term of this License Agreement Agreement, regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan States and European patent office counterparts with respect to the United States, Japan States and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 8 and 9, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Bukwang Patents, Pharmasset Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 68, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio Each party will require all of its and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree thatits Affiliates’ employees to assign all Inventions that are the subject of patent applications claiming Inventions that are developed, during made or conceived by such employees according to the term of any sublicensee agreement, the rights of Novirio under ownership principles described in this Article 6 shall be exercised8. Each party will require any agents or independent contractors performing an activity pursuant to this Agreement to assign all Inventions that are the subject of patent applications Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, if at allwhich are marked with brackets and asterisks [***], have been separately filed with the Commission. claiming Inventions that are developed, made or conceived by its sublicense with respect such agents or independent contractors to all patent prosecution activities Bukwang and/or Pharmasset according to the ownership principles described in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directlythis Article 8.

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 78, each party's ’s responsibilities for patent prosecution activities pursuant to this Article 6 7 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's ’s or its sublicensee's ’s position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicenseessublicensee, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 67, each party undertakes to keep the other party and, if applicable applicable, such other party's ’s sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, this License Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees sublicensee in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 7, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 67, it shall give the other party or its sublicense sublicensee notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. (c) Novirio BUKWANG and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR agree that, during the term of any sublicensee agreementthe Triangle Sublicense Agreement, the rights of Novirio BUKWANG under this Article 6 7 shall be exercised, if at all, by its sublicense TRIANGLE with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement the Triangle Sublicense Agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR shall communicate with such sublicensee TRIANGLE directly.

Appears in 2 contracts

Sources: License Agreement (Pharmasset Inc), License Agreement (Pharmasset Inc)

Further Obligations. (a) Except as otherwise provided in Article 7, each party's responsibilities for patent prosecution activities pursuant to this Article 6 shall also include ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, (which term as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary License, each party hereto shall use the patent attorneys selected by UAB. In addition to the other obligations set forth in this Article 6, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with the correspondents with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 6, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ Dr. Schinazi agree that, during the term of any sublicensee agreementagreemen▇, the rights ▇▇▇ ▇▇▇▇▇s of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ Dr. Schinazi shall communicate with such sublicensee directly.

Appears in 1 contract

Sources: License Agreement (Novirio Pharmaceuticals LTD)

Further Obligations. (a) Except as otherwise provided in Article 7Articles 11 and 20, each party's responsibilities for patent prosecution activities pursuant to this Article 6 10 shall also include all ex parte and inter partes activities relating to the defending such party's relevant patent applications and patents, including all interference, opposition defense and observation defense proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph Subsection 10.5 (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit and reasonably acceptable to the other party. In addition to the other obligations set forth in this Article 610, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable ---------- *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to offices in the United States, Japan and European patents and patent applicationsPatent Filing Countries. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 10 and 11, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Dynavax Patents, Triangle Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 610, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] * (***) days before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇Each party shall have the independent right to challenge third party patents or patent applications which may, in such party's sole discretion, affect the ability to commercialize Licensed Products. ▇▇▇▇▇▇▇▇ agree that, during The party choosing to challenge such third party patents or patent applications shall advise the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion other party of the Licensed Territory challenge in which a sublicense agreement is then in effect. With respect writing at least thirty (30) days prior to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directlyinitiating the challenge.

Appears in 1 contract

Sources: License Agreement (Triangle Pharmaceuticals Inc)

Further Obligations. (a) Except as otherwise provided in Article 78, each party's responsibilities for patent prosecution activities pursuant to this Article 6 7 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicenseessublicensee, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 67, each party undertakes to keep the other party and, if applicable applicable, such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, this License Agreement including, but not limited to, supplying the other party or its sublicensee, as applicable, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees sublicensee in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 7, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Patents, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 67, it shall give the other party or its sublicense sublicensee notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts *** to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. (c) Novirio BUKWANG and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR agree that, during the term of any sublicensee agreementthe Triangle Sublicense Agreement, the rights of Novirio BUKWANG under this Article 6 7 shall be exercised, if at all, by its sublicense TRIANGLE with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement the Triangle Sublicense Agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ LICENSOR shall communicate with such sublicensee TRIANGLE directly.

Appears in 1 contract

Sources: License Agreement (Triangle Pharmaceuticals Inc)

Further Obligations. (a) Except as otherwise provided in Article 7Articles 11 and 20, each party's responsibilities for patent prosecution activities pursuant to this Article 6 10 shall also include all ex parte and inter partes activities relating to the defending such party's relevant patent applications and patents, including all interference, opposition defense and observation defense proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph Subsection 10.5 (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit and reasonably acceptable to the other party. In addition to the other obligations set forth in this Article 610, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to offices in the United States, Japan and European patents and patent applicationsPatent Filing Countries. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 10 and 11, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Dynavax Patents, Triangle Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 610, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] days * before any abandonment, lapse or any other relevant deadline. (c) Novirio and TherapX and ▇▇Each party shall have the independent right to challenge third party patents or patent applications which may, in such party's sole discretion, affect the ability to commercialize Licensed Products. ▇▇▇▇▇▇▇▇ agree that, during The party choosing to challenge such third party patents or patent applications shall advise the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion other party of the Licensed Territory challenge in which a sublicense agreement is then in effect. With respect writing at least thirty (30) days prior to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directlyinitiating the challenge.

Appears in 1 contract

Sources: License Agreement (Triangle Pharmaceuticals Inc)

Further Obligations. (a) Except as otherwise provided in Article 7Articles 9 and 18, each party's responsibilities for patent prosecution activities pursuant to this Article 6 8 shall also include all ex parte and inter partes activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes activities of the type described in the first sentence of this subparagraph Subsection 8.5 (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 68, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervals, with the correspondents all correspondence with the United States, Japan and European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 8 and 9, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Bukwang Patents, Triangle Patents or those relating to Joint Inventions, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 68, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts *** to give such notice at least [**] sixty (60) days before any abandonment, lapse or any other relevant deadline. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 1 contract

Sources: License Agreement (Triangle Pharmaceuticals Inc)

Further Obligations. (a) Except as otherwise provided in Article 7Articles 8 and 15, each party's responsibilities for patent prosecution activities pursuant to this Article 6 7 shall also include ex parte all other EX PARTE and inter partes INTER PARTES activities relating to the relevant patent applications and patents, including all interference, opposition and observation proceedings before any patent offices and litigation pertaining to determine the validity, enforceability, allowability or subsistence of such patent applications and patents. Each party agrees to give due consideration to the other party's or its sublicensee's position with respect to any such patent prosecution activities, activities (which term term, as used herein, shall include without limitation, any inter partes INTER PARTES activities of the type described in the first sentence of this subparagraph subsection 7.5 (a)). In the event a party fails to initiate or pursue any patent prosecution activities for which it is responsible, or having commenced such patent prosecution activities, declines to pursue such patent prosecution activities, it shall give notice to the other party pursuant to the applicable provisions of subparagraph (b) below and the other party or its sublicensees, as applicable, may initiate, pursue or assume such patent prosecution activities, at its sole expense; provided, however, that in the case of Triangle's initiation, pursuit or assumption of patent prosecution activities in respect of Mitsubishi Patents in a given country, Triangle shall be able to credit the out-of-pocket expenses so incurred against earned royalties due hereunder with respect to Licensed Products sold in such *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. (b) In conducting its patent prosecution activities under this License Agreement in compliance with the provisions of the Primary LicenseAgreement, each party hereto shall may use the patent attorneys selected by UABit in its own discretion. In addition to the other obligations set forth in this Article 67, each party undertakes to keep the other party and, if applicable such other party's sublicensee throughout the term of this License Agreement regularly informed of the status and progress of the patent prosecution activities it undertakes under this, License this Agreement including, but not limited to, supplying the other party or its sublicensee, as applicableother, upon reasonable request and at reasonable intervalsrequest, with the correspondents all correspondence with the United States, Japan and or European patent office counterparts with respect to the United States, Japan and European patents and patent applications. To the extent that a party has not previously done so, or promptly upon request by the other party or its sublicensee, in order to assist such other party or its sublicensees in connection with any of its activities or the exercise of any of its rights pursuant to Article 6Articles 7 and 8, such party shall provide the other party or its sublicensee with such additional relevant documentation which such other party or its sublicensee may reasonably request relating to such patent applications and patents in the Licensed Mitsubishi Patents or Triangle Patents, as applicable, including but not limited to, copies thereof and access to laboratory notebooks, other supporting data and relevant employees. If a party decides to abandon or allow to lapse any patent application or patent or not to initiate or any other patent prosecution activity for which it has patent prosecution responsibility pursuant to this Article 67, it shall give the other party or its sublicense notice thereof in a sufficiently timely manner so as to enable such other party or its sublicensee to determine whether to assume patent prosecution activity in connection therewith. Each party shall use its best efforts to give such notice at least [**] days * before any abandonment, lapse or any other relevant deadline. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. (c) Novirio and TherapX and ▇▇. ▇▇▇▇▇▇▇▇ agree that, during the term of any sublicensee agreement, the rights of Novirio under this Article 6 shall be exercised, if at all, by its sublicense with respect to all patent prosecution activities in any portion of the Licensed Territory in which a sublicense agreement is then in effect. With respect to such patent prosecution activities, TherapX and ▇▇. ▇▇▇▇▇▇▇▇ shall communicate with such sublicensee directly.

Appears in 1 contract

Sources: License Agreement (Triangle Pharmaceuticals Inc)